Creative Diagnostics has developed the highly sensitive monoclonal antibody pairs against the nucleoprotein antigens of SARS-CoV-2. These antibodies were screened from thousands of clones and selected for their high sensitivity and specificity in lateral flow applications.
Antibodies are validated for rapid antigen tests and used in commercially available assays globally
The confirmed LOD for direct swab is 1.5 x 102 TCID50/mL
Can also detect D614G strain; no cross reactivity to other coronaviruses
Used in assays for nasopharyngeal swab or saliva specimens
Can be manufactured in small or large scales (mg to g)
We remain focused on our mission to serve life scientists to achieve their mission, faster. We know that many scientists are still diligently pursuing their research, and we'll continue to support our customers and partners worldwide.
As a global supplier for research products, Creative Diagnostics has developed a large panel of reagents for COVID-19 research. Several of our monoclonal antibodies have been used in COVID-19 antigen rapid test production... Learn more
Creative Diagnostics can provide SARS-CoV-2 Spike/RBD mutants, expressed in HEK293 cells. Antigens are post-translationally modified (glycosylation and phosphorylation) and more closely resembled the native viral proteins that can overcome specificity issues... Learn more
To understand the cell entry mechanism of SARS-CoV-2, it is essential to study how Spike proteins interact with the ACE2 receptor. However, such studies are hampered by the danger of producing and manipulating live coronavirus... Learn more
FOLLOW US
Creative Diagnostics · 45-1 Ramsey Road · Shirley · New York · 11967
